Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 45 of 116

  1. DS3201-330

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. DS7300-189

    Daiichi Sankyo

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  3. DSC/11/2357/44

    Italfarmaco S.p.A.

    Chronic myeloproliferative neoplasm

    phase 2 small molecule active

    1 trial

  4. DURVALUMAB

    Fondazione Telethon ETS

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  6. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  7. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  8. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Danggui Buxue Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  10. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  11. Darinaparsin

    Alaunos Therapeutics

    HEPATOCELLULAR CARCINOMA

    phase 2 small molecule active

    1 trial

  12. Darinaparsin

    Alaunos Therapeutics

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  13. Darleukin, Fibromun

    Philogen S.p.A.

    locally advanced basal cell carcinoma patients

    phase 2 small molecule active

    1 trial

  14. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  15. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  16. Darovasertib

    Hospital Authority, Hong Kong

    Ocular Melanoma

    phase 2 small molecule completed

    1 trial

  17. Dasatinib

    Bristol-Myers Squibb

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  18. Dasatinib

    Takeda

    Acute Lymphoblastic Leukemia

    phase 2 small molecule terminated

    1 trial

  19. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

  21. Dazostinag

    Takeda

    Solid Neoplasms

    phase 2 small molecule completed

    1 trial

  22. Debio 4228, Debio 4228

    Alphapharm Pty Ltd

    advanced prostate cancer

    phase 2 small molecule active

    1 trial

  23. Decitabine

    Shanghai Tong Ren Hospital

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  24. Decitabine

    Karyopharm Therapeutics Inc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  25. Decitabine

    CATALYST PHARMACEUTICALS, INC.

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  26. Decitabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  27. Decitabine

    The University of Hong Kong

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  28. Decoy20

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  29. Degarelix

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  30. Demcizumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 2 small molecule completed

    2 trials

  31. Dendritic Cell Vaccination

    Quantum Biopharma

    Breast Cancer

    phase 2 mab active

    1 trial

  32. Dendritic Cell/Tumor Fusion Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 mab terminated

    1 trial

  33. Denosumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

  34. Dental stent

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  35. Derazantinib

    Basilea Pharmaceutica

    Gastric Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  36. Dexamethasone

    Kura Oncology

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  37. Dexamethasone

    The First People's Hospital of Lianyungang

    Precursor B-Cell Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  38. Dietary

    The University of Hong Kong

    Colorectal Cancer

    phase 2 other active

    1 trial

  39. Disitamab Vedotin

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  40. Disitamab Vedotin

    Pfizer Australia Pty Ltd

    HER2 Expressing Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  41. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  42. Docetaxel

    Takeda

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  43. Docetaxel

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  44. Docetaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  45. Docetaxel

    Karyopharm Therapeutics Inc

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  46. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  47. Docetaxel + Sunitinib

    Samsung Bioepis NL B.V.

    Advanced Gastric Cancer

    phase 2 small molecule completed

    1 trial

  48. Docetaxel, Reolysin and Prednisone

    ONCOLYTICS BIOTECH INC

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.